These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 25623164)

  • 1. Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment.
    Zippelius A; Schreiner J; Herzig P; Müller P
    Cancer Immunol Res; 2015 Mar; 3(3):236-44. PubMed ID: 25623164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model.
    Luheshi NM; Coates-Ulrichsen J; Harper J; Mullins S; Sulikowski MG; Martin P; Brown L; Lewis A; Davies G; Morrow M; Wilkinson RW
    Oncotarget; 2016 Apr; 7(14):18508-20. PubMed ID: 26918344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.
    Liu L; Mayes PA; Eastman S; Shi H; Yadavilli S; Zhang T; Yang J; Seestaller-Wehr L; Zhang SY; Hopson C; Tsvetkov L; Jing J; Zhang S; Smothers J; Hoos A
    Clin Cancer Res; 2015 Apr; 21(7):1639-51. PubMed ID: 25589619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
    Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
    Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1/PD-1 signal deficiency promotes allogeneic immune responses and accelerates heart allograft rejection.
    Wang W; Carper K; Malone F; Latchman Y; Perkins J; Fu Y; Reyes J; Li W
    Transplantation; 2008 Sep; 86(6):836-44. PubMed ID: 18813109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor.
    Prosser ME; Brown CE; Shami AF; Forman SJ; Jensen MC
    Mol Immunol; 2012 Jul; 51(3-4):263-72. PubMed ID: 22503210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.
    Abiko K; Matsumura N; Hamanishi J; Horikawa N; Murakami R; Yamaguchi K; Yoshioka Y; Baba T; Konishi I; Mandai M
    Br J Cancer; 2015 Apr; 112(9):1501-9. PubMed ID: 25867264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
    Mangsbo SM; Sandin LC; Anger K; Korman AJ; Loskog A; Tötterman TH
    J Immunother; 2010 Apr; 33(3):225-35. PubMed ID: 20445343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic CD40 signaling on APCs and CD8 T cells drives efficient CD8 response and memory differentiation.
    Meunier S; Rapetti L; Beziaud L; Pontoux C; Legrand A; Tanchot C
    J Leukoc Biol; 2012 Jun; 91(6):859-69. PubMed ID: 22241832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different costimulation signals used by CD4(+) and CD8(+) cells that independently initiate rejection of allogenic hepatocytes in mice.
    Gao D; Li J; Orosz CG; Bumgardner GL
    Hepatology; 2000 Nov; 32(5):1018-28. PubMed ID: 11050052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced tumor-antigen density leads to PD-1/PD-L1-mediated impairment of partially exhausted CD8⁺ T cells.
    Kaiser AD; Schuster K; Gadiot J; Borkner L; Daebritz H; Schmitt C; Andreesen R; Blank C
    Eur J Immunol; 2012 Mar; 42(3):662-71. PubMed ID: 22144176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses.
    Beavis PA; Milenkovski N; Henderson MA; John LB; Allard B; Loi S; Kershaw MH; Stagg J; Darcy PK
    Cancer Immunol Res; 2015 May; 3(5):506-17. PubMed ID: 25672397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
    Stewart R; Morrow M; Hammond SA; Mulgrew K; Marcus D; Poon E; Watkins A; Mullins S; Chodorge M; Andrews J; Bannister D; Dick E; Crawford N; Parmentier J; Alimzhanov M; Babcook JS; Foltz IN; Buchanan A; Bedian V; Wilkinson RW; McCourt M
    Cancer Immunol Res; 2015 Sep; 3(9):1052-62. PubMed ID: 25943534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4 T Cell Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply Exhausted CD8 T Cells.
    Penaloza-MacMaster P; Provine NM; Blass E; Barouch DH
    J Immunol; 2015 Aug; 195(3):1054-63. PubMed ID: 26116499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment.
    Xiong H; Mittman S; Rodriguez R; Moskalenko M; Pacheco-Sanchez P; Yang Y; Nickles D; Cubas R
    Cancer Res; 2019 Apr; 79(7):1493-1506. PubMed ID: 30679180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.
    Homet Moreno B; Zaretsky JM; Garcia-Diaz A; Tsoi J; Parisi G; Robert L; Meeth K; Ndoye A; Bosenberg M; Weeraratna AT; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Ribas A
    Cancer Immunol Res; 2016 Oct; 4(10):845-857. PubMed ID: 27589875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells.
    Latchman YE; Liang SC; Wu Y; Chernova T; Sobel RA; Klemm M; Kuchroo VK; Freeman GJ; Sharpe AH
    Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10691-6. PubMed ID: 15249675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutting edge: identification of autoreactive CD4+ and CD8+ T cell subsets resistant to PD-1 pathway blockade.
    Pauken KE; Nelson CE; Martinov T; Spanier JA; Heffernan JR; Sahli NL; Quarnstrom CF; Osum KC; Schenkel JM; Jenkins MK; Blazar BR; Vezys V; Fife BT
    J Immunol; 2015 Apr; 194(8):3551-3555. PubMed ID: 25769925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.